Approval Package for:

APPLICATION NUMBER:
NDA 20-717/S-003

Name: Provigil Tablets

Generic Name: modafinil

Sponsor: Cephalon, Inc.

Approval Date: 09/19/00
## Review

<table>
<thead>
<tr>
<th>Reviews / Information Included in this Review</th>
</tr>
</thead>
<tbody>
<tr>
<td>Approval Letter</td>
</tr>
<tr>
<td>Approvable Letter(s)</td>
</tr>
<tr>
<td>Final Printed Labeling</td>
</tr>
<tr>
<td>Medical Review(s)</td>
</tr>
<tr>
<td>Chemistry Review(s)</td>
</tr>
<tr>
<td>EA/FONSI</td>
</tr>
<tr>
<td>Pharmacology Review(s)</td>
</tr>
<tr>
<td>Statistical Review(s)</td>
</tr>
<tr>
<td>Microbiology Review(s)</td>
</tr>
<tr>
<td>Clinical Pharmacology/Biopharmaceutics Review(s)</td>
</tr>
<tr>
<td>Administrative and Correspondence Document(s)</td>
</tr>
</tbody>
</table>
CENTERS FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:
NDA 20-717/S-003

APPROVAL LETTER
NDA 20-717/S-003

Cephalon, Inc.
Attention: Paul M. Kirsch
Director – U.S. Regulatory Operations
145 Brandywine Parkway
West Chester, PA 19380-4245

Dear Mr. Kirsch:

Please refer to your supplemental new drug application dated August 15, 2000, received August 16, 2000, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for PROVIGIL® (modafinil) Tablets 100 mg and 200 mg.

We acknowledge receipt of your submission dated August 15, 2000, received September 15, 2000.

This "Changes Being Effected" supplemental new drug application provides for a revision of the specifications and procedures for the drug product, Provigil.

We have completed the review of this supplemental new drug application, as amended, and it is approved.

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, call Anna Marie Homonnay, R.Ph., Regulatory Management Officer, at (301) 594-2850.

Sincerely,

Maryla Guzewska, Ph.D.
Chemistry Team Leader, Neurology Drugs for the Division of Neuropharmacological Drug Products, (HFD-120)
DNDC I, Office of New Drug Chemistry
Center for Drug Evaluation and Research
CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:
NDA 20-717/S-003

CHEMISTRY REVIEW(S)
CHEMIST'S REVIEW
OF SUPPLEMENT

ORGANIZATION: HFD-120
NDA NUMBER: 20-717
SUPPLEMENT NUMBER: SCS-003
LETTER DATE 15-AUG-00
STAMP DATE 16-AUG-00
AMENDMENTS/REPORTS:
LETTER DATE 15-AUG-00
STAMP DATE 15-SEP-00
RECEIVED BY CHEMIST: 06-SEP-00

APPLICANT NAME AND ADDRESS: CEPHALON
145 Brandywine Parkway
West Chester, PA 19380-4245

NAME OF DRUG: PROVIGIL®
NONPROPRIETARY NAME: Modafinil
CHEMICAL NAME / STRUCTURE: 2-[[Diphenylmethyl]sulfonyl]acetamide
DOSEAGE FORM(S): Tablet (oral)
POTENCY(IES): 100 mg and 200 mg
PHARMACOLOGICAL CATEGORY: To improve wakefulness in patients with excessive daytime sleepiness associated with narcolepsy.

HOW DISPENSED: XX (Rx)
RECORDS / REPORTS CURRENT: XX (YES)
RELATED IND / NDA / DMF(S): N/A

SUPPLEMENT PROVIDES FOR: Revision of the specifications and procedures for the drug product, Provigil (CBE-30).

COMMENTS: The firm provides copies of the revised specifications and methods (release and stability) for the 100 mg and 200 mg tablets. The references to USP 23 are changed to USP 24. The firm has implemented other minor changes. A copy of the revised cover letter is provided in Attachment 1.

CONCLUSIONS AND RECOMMENDATIONS: APPROVAL

REVIEWER NAME David J. Cummings
SIGNATURE
DATE COMPLETED September 19, 2000

cc: Orig.; NDA 20-717
HFD-120/Div. File
HFD-120/AHornmonay
HFD-120/DJCummings
HFD-120/MHeimann
INIT: MGuzewska/

Filename: N20717S3
Redacted 6 page(s) of trade secret and/or confidential commercial information from 5-003. Chemistry Review